55 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization.
Shandong University
Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8.
University of North Carolina at Chapel Hill
Identifying novel selective non-nucleoside DNA methyltransferase 1 inhibitors through docking-based virtual screening.
Chinese Academy of Sciences
Analogues of the Natural Product Sinefungin as Inhibitors of EHMT1 and EHMT2.
University of Copenhagen
Selective non-nucleoside inhibitors of human DNA methyltransferases active in cancer including in cancer stem cells.
Sapienza University of Rome
Synthetic approaches to DNMT inhibitor SGI-1027 and effects on the U937 leukemia cell line.
Universidade De Vigo
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2.
TBA
Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets.
Imperial College
Development of rationally designed DNA N6 adenine methyltransferase inhibitors.
University of Southampton
Synthesis and biochemical evaluation ofd(2)-isoxazoline derivatives as DNA methyltransferase 1 inhibitors.
University of Salerno
Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation.
Deutsches Krebsforschungszentrum
Constrained (l-)-S-adenosyl-l-homocysteine (SAH) analogues as DNA methyltransferase inhibitors.
Methylgene
SAR around (l)-S-adenosyl-l-homocysteine, an inhibitor of human DNA methyltransferase (DNMT) enzymes.
Methylgene
An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.
UNC Eshelman School of Pharmacy
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.
University of Cambridge
Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.
Daiichi Sankyo Co., Ltd
Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2.
Sun Yat-Sen University
Hydroxamic acid hybrids: Histone deacetylase inhibitors with anticancer therapeutic potency.
Shandong University
Development of a First-in-Class DNMT1/HDAC Inhibitor with Improved Therapeutic Potential and Potentiated Antitumor Immunity.
Shandong University
Discovery of a Highly Potent Lysine Methyltransferases G9a/NSD2 Dual Inhibitor to Treat Solid Tumors.
Sun Yat-Sen University
Identification of 3-(9H-carbazol-9-yl)-2-(1,3-dioxoisoindolin-2-yl)propanoic acids as promising DNMT1 inhibitors.
Fudan University
Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment.
Guru Ghasidas University
Sticklac-Derived Natural Compounds Inhibiting RNase H Activity of HIV-1 Reverse Transcriptase.
Chiba University
Discovery of novel non-nucleoside inhibitors with high potency and selectivity for DNA methyltransferase 3A.
Zhejiang University
Structure-Based Design and Characterization of the Highly Potent and Selective Covalent Inhibitors Targeting the Lysine Methyltransferases G9a/GLP.
Sun Yat-Sen University
Discovery of a New-Generation S-Adenosylmethionine-Noncompetitive Covalent Inhibitor Targeting the Lysine Methyltransferase Enhancer of Zeste Homologue 2.
Sun Yat-Sen University
Quinoline anticancer agents active on DNA and DNA-interacting proteins: From classical to emerging therapeutic targets.
University of Palermo
Discovery of two novel, small-molecule inhibitors of DNA methylation.
Polish Academy of Sciences
Discovery of AL-GDa62 as a Potential Synthetic Lethal Lead for the Treatment of Gastric Cancer.
Victoria University of Wellington
Discovery of the first chemical tools to regulate MKK3-mediated MYC activation in cancer.
Emory University School of Medicine
Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with
University of Navarra
Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment.
Southern Medical University
Identification of DOT1L inhibitors by structure-based virtual screening adapted from a nucleoside-focused library.
University of Michigan Medical School
New small molecule inhibitors of histone methyl transferase DOT1L with a nitrile as a non-traditional replacement for heavy halogen atoms.
University College London
Synthesis of NSC 106084 and NSC 14778 and evaluation of their DNMT inhibitory activity.
University of Montreal
Discovery of a Novel Chemotype of Histone Lysine Methyltransferase EHMT1/2 (GLP/G9a) Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Co-crystal Structure.
The University of Texas M.D. Anderson Cancer Center
Identification of novel quinazoline derivatives as potent antiplasmodial agents.
University of Lille
Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
National University of Singapore
Synthesis and evaluation of analogues of N-phthaloyl-l-tryptophan (RG108) as inhibitors of DNA methyltransferase 1.
Pierre and Marie Curie University
Design, synthesis and in vitro anti-Zika virus evaluation of novel Sinefungin derivatives.
Peking Union Medical College
Identification of novel inhibitors of histone acetyltransferase hMOF through high throughput screening.
Chinese Academy of Sciences
Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces.
Wuxi Apptec (Tianjin) Co.
Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy.
Universidad De Oviedo-Principado De Asturias
Rational Design of Bisubstrate-Type Analogues as Inhibitors of DNA Methyltransferases in Cancer Cells.
Cnrs-Pierre Fabre Usr3388
